In the field of antifungal pharmaceutical raw materials, Bulk Liranaftate (CAS No. 88678-31-3) has become a first-line raw material choice for treating fungal skin diseases due to its core advantages of "highly effective targeting, low toxicity and mildness, and low likelihood of drug resistance." As a typical representative of thiocarbamate antifungal raw materials, it is not a natural extract, but a high-purity raw material precisely prepared through chemical synthesis technology. It is specifically designed to target common pathogenic fungi such as dermatophytes and yeasts, which can rapidly inhibit fungal proliferation while avoiding damage to normal human skin cells, perfectly balancing "antibacterial strength" and "drug safety." From clinically commonly used topical ointments and creams to home antifungal sprays and powders, Bulk Liranaftate maintains its core position in the field of antifungal raw materials for skin diseases thanks to its stable physicochemical properties, clear mechanism of action, and abundant clinical data.
The "Ingenious Design" of the Thiocarbamate Family
The chemical name of liranaftate is rather tongue-twisting: O-(5,6,7,8-tetrahydronaphthyl-2-yl)N-(6-methoxypyridin-2-yl)-N-methylthiocarbamate. Its molecular formula is C₁₈H₂₀N₂O₂S, its molecular weight is 328.43 g/mol, and its CAS number is 88678-31-3. This molecule has several noteworthy structural features: the "tetrahydronaphthyl ring," a bicyclic system composed of a benzene ring and cyclohexane, provides the molecule with rigidity and hydrophobicity. Hydrophobicity is crucial for penetrating the lipid-rich stratum corneum of skin-where fungi precisely hide. The "thiocarbamate" core is the "active heart" of the entire molecule. The difference between thiocarbamate and ordinary carbamate is that the carbonyl group is replaced by a thiocarbonyl group. This seemingly minor change endows the molecule with the specificity to bind to fungal targets. The methoxypyridine side chain, with its methoxy group on the pyridine ring, not only increases the lipophilicity of the molecule but also participates in hydrogen bond interactions with the active site of squalene epoxidase.
The molecular structure of Bulk Liranaftate is closely related to its antibacterial activity, transdermal properties, and safety. The synergistic effect of its three functional units distinguishes it from traditional antifungal raw materials and gives it unique advantages of "high efficiency, low toxicity, and targeted therapy." Based on experimental data and raw material development practice, the relationship between its structure and activity can be explored from three aspects, clarifying the role of structural optimization in improving raw material performance:
- First, the pharmacophore structure determines the antibacterial strength and antibacterial spectrum. The structural integrity of the thiocarbamate group directly affects its inhibitory ability against fungal squalene epoxidase. Experiments show that when the sulfur atom in the thiocarbamate group is replaced by an oxygen atom, the MIC of the raw material against Trichophyton rubrum increases from 0.009 μg/mL to 0.8 μg/mL, and the antibacterial activity decreases by 88%. When the amino group is replaced by a methyl group, the antibacterial activity decreases by 75%, and the antibacterial spectrum narrows, becoming effective only against Trichophyton rubrum, with significantly weakened inhibitory effects against Trichophyton mentagrophytes and Candida albicans. Furthermore, Bulk Liranaftate exhibits a broad antibacterial spectrum, inhibiting various dermatopathogenic fungi. In vitro experiments showed that its MICs against *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Microsporum canis* were 0.009 μg/mL, 0.018 μg/mL, and 0.036 μg/mL, respectively, all lower than the traditional antifungal agent clotrimazole, confirming its superior antibacterial strength. In an in vitro antibacterial experiment, researchers selected 200 clinically isolated dermatophytes and tested the antibacterial effects of Bulk Liranaftate and clotrimazole. The results showed that Bulk Liranaftate inhibited all strains by ≥90%, while clotrimazole's inhibition rate was 78%-85%. Especially against resistant strains, Bulk Liranaftate showed a more significant advantage; the MIC for resistant strains was only 0.072 μg/mL, while clotrimazole's MIC was as high as 0.96 μg/mL.
- Secondly, the lipophilic group determines transdermal efficiency and local accumulation capacity. The lipophilicity of the tetrahydronaphthyl group directly affects the transdermal absorption rate and skin residence time. Experiments comparing liranaftate derivatives modified with different lipophilic groups revealed that the tetrahydronaphthyl-modified derivative had a significantly higher transdermal absorption rate than the benzene ring-modified and cyclohexyl-modified derivatives, and a skin residence time as long as 14 hours, while the benzene ring-modified derivative's residence time was only 6 hours. Regarding local accumulation capacity, Bulk Liranaftate reached a concentration of 12.8 μg/cm² at the site of skin infection, while the concentration in blood was only 0.02 μg/mL, far below the toxic dose. This confirms that it can efficiently accumulate locally in the skin, exerting a long-lasting antibacterial effect while avoiding the toxic side effects of systemic absorption. In a human clinical trial, 100 patients with tinea pedis applied a cream containing 2% Bulk Liranaftate daily for 7 consecutive days. The concentration of the active ingredient in the skin infection site and blood was measured. The results showed that the peak local concentration in the skin was 15.3 μg/cm², while no significant amount of the active ingredient was detected in the blood, confirming its excellent local accumulation and good safety profile.
- Third, the targeting side chain determines the safety and tolerability of the drug. The presence of the methoxypyridine amino side chain allows Bulk Liranaftate to specifically recognize fungal cells, reducing damage to normal skin cells and lowering the risk of skin irritation. Clinical data show that the incidence of skin irritation using topical preparations containing Bulk Liranaftate was only 1.86%, far lower than that of clotrimazole preparations. In a clinical trial involving 1611 subjects, the incidence of adverse reactions was 30 cases, primarily contact dermatitis, itching, redness, and erythema, pain, and irritation. Most adverse reactions were mild and resolved spontaneously after discontinuation of the drug. Furthermore, when the targeted side chain was removed, the toxicity of the raw material to normal skin cells significantly increased, with TC50 decreasing from 15 μg/mL to 2.3 μg/mL, and the incidence of skin irritation rising to 8.7%, confirming the important role of the targeted side chain in ensuring drug safety.
In summary, the molecular structure design of Bulk Liranaftate combines three major advantages: "highly effective antibacterial activity, precise transdermal penetration, and low toxicity and safety." The synergistic effect of its three functional units not only solves the problems of low transdermal efficiency and insufficient antibacterial strength of traditional antifungal raw materials but also overcomes their drawbacks of high skin irritation and easy systemic absorption, laying a solid molecular foundation for its widespread application as a skin antifungal raw material.
Multi-pathway synergistic "fungal targeted inhibition mechanism"
Bulk Liranaftate, a thiocarbamate antifungal agent, primarily targets squalene epoxidase within fungal cells. This enzyme is the rate-limiting enzyme in the synthesis of ergosterol, a key component of the fungal cell membrane. Its activity directly determines the efficiency of ergosterol synthesis, which is essential for maintaining the integrity, fluidity, and permeability of the fungal cell membrane. If synthesis is inhibited, fungal cells cannot survive normally.
Bulk Liranaftate, through its thiocarbamate pharmacophore, specifically binds to the active site of fungal squalene epoxidase, forming a stable complex that inhibits the enzyme's activity and blocks ergosterol synthesis. In vitro experiments show that Bulk Liranaftate has a half-maximal inhibitory concentration (IC50) of 0.004 μg/mL against fungal squalene epoxidase, while exhibiting no significant inhibitory effect on human squalene epoxidase, demonstrating its high target specificity and ability to inhibit fungi without damaging normal human cells.
Specifically, in the synthesis of ergosterol, squalene is oxidized to 2,3-oxidized squalene by squalene epoxidase, and then gradually converted into ergosterol. When Bulk Liranaftate inhibits squalene epoxidase, the oxidation process of squalene is blocked, leading to a large accumulation of squalene in fungal cells, while the synthesis of ergosterol is significantly reduced. Experiments showed that after adding 0.01 μg/mL of Bulk Liranaftate, the squalene content in Trichophyton rubrum cells increased by 8.7 times, while the ergosterol content decreased by 78%. This dual effect of "squalene accumulation + ergosterol deficiency" directly disrupts the integrity of the fungal cell membrane.
Squalene, a hydrophobic substance, accumulates in large quantities within fungal cell membranes, disrupting the lipid bilayer structure and increasing permeability, leading to significant loss of essential intracellular substances such as electrolytes and proteins. Simultaneously, ergosterol deficiency reduces cell membrane fluidity, hindering the maintenance of normal cell morphology and ultimately causing fungal cell lysis and death. In an in vitro bactericidal experiment, co-culturing *Trichophyton rubrum* with 0.009 μg/mL Bulk Liranaftate resulted in a fungal cell mortality rate exceeding 95% after 72 hours, compared to only 3.2% in the control group without Bulk Liranaftate. This clearly demonstrates that Bulk Liranaftate exerts its bactericidal effect by inhibiting squalene epoxidase.
Furthermore, the inhibitory effect of Bulk Liranaftate on drug-resistant strains is also related to the conservation of squalene epoxidase. Traditional antifungal agents target ergosterol on the fungal cell membrane, which is prone to resistance due to structural mutations in ergosterol. However, squalene cyclooxygenase is highly conserved in fungal cells with an extremely low mutation rate, making Bulk Liranaftate less likely to induce resistance. In vitro experiments showed that after 20 generations of continuous culture of Trichophyton rubrum, its MIC against Bulk Liranaftate did not change significantly, while its MIC against clotrimazole increased by 8 times, confirming its advantage in drug resistance.
In clinical applications, the mechanism of action of Bulk Liranaftate determines its applicability and advantages. For example, its high target specificity makes it suitable for special populations such as those with sensitive skin, children, and the elderly; it is less likely to induce drug resistance, making it suitable for infections caused by drug-resistant strains; and it can regulate the skin microecology, making it suitable for long-term use and reducing recurrence rates. These advantages all stem from its unique mechanism of action, which is also the core difference between it and traditional antifungal raw materials.
In summary, the mechanism of action of Bulk Liranaftate is characterized by "precision, synergy, and scientific rigor." Its core mechanism is to achieve highly effective antibacterial activity by inhibiting squalene epoxidase, while its efficacy is enhanced by disrupting cell membranes, inhibiting metabolism, and regulating the microecology, forming a comprehensive antibacterial network. As pharmaceutical raw material experts, a deep understanding of its mechanism of action can provide scientific guidance for raw material quality control, formulation optimization, and clinical application. For example, in formulation design, its mechanism of action can be combined with moisturizing and skin-repairing ingredients to repair the skin barrier while inhibiting bacteria; in quality control, its ability to inhibit squalene epoxidase can be tested to verify the bioactivity of the raw material and ensure its quality.
"Functional expansion" from sterilization to anti-inflammation
In traditional antifungal treatments, even after the fungus is eradicated, residual inflammation can lead to persistent itching and tissue damage. Liranaftate's "dual-action" mechanism-antibacterial + anti-inflammatory-may offer unique advantages in improving patient symptoms and shortening the period of discomfort. This discovery provides new scientific evidence for the clinical application of Liranaftate: it may be particularly suitable for patients with severe tinea corporis, tinea cruris, and tinea pedis.
With the widespread use of antifungal drugs, drug resistance is becoming an increasingly serious challenge. Research focus is shifting towards squalene epoxidase mutations. It is known that some fungi reduce their sensitivity to allylamines and thiocarbamates through point mutations in the SQLE gene. What is the risk of resistance to liranaftate? Theoretically, because its binding mechanism with SQLE differs from terbinafine, cross-resistance may not be complete. However, this question still requires further research to answer. For companies manufacturing and researching bulk liranaftate, developing "next-generation" molecules without cross-resistance to liranaftate may be a potential direction.
In summary, the latest research on Bulk Liranaftate revolves around "technology optimization, cost reduction, and application expansion." It improves bioavailability through targeted delivery technology, reduces production costs through green synthesis processes, and expands application boundaries through the discovery of new efficacy, providing new ideas for its large-scale application and industrial upgrading.
Conclusion
The story of liranaftate is essentially a story of "differentiated competition." In the crowded antifungal drug market, it has found its niche with a combination of "bactericidal" and "anti-inflammatory" effects. It's not a "miracle drug" or a "one-size-fits-all," but for patients plagued by recurring, intractable athlete's foot and disillusioned with traditional treatments, liranaftate offers a new and worthwhile option.
Its future depends on two things: first, more high-quality head-to-head clinical trials demonstrating its superiority or equivalence compared to terbinafine and azole drugs; and second, favorable market promotion and health insurance policies. If both come into play, this "thiocarbamate" has the potential to grow from a "low-key powerhouse" into a "mainstream player" in the treatment of dermatophyte infections.
Xi'an Faithful BioTech Co., Ltd. understands the importance of high-quality pharmaceutical raw materials for formulation. Our Bulk Liranaftate is produced to the highest standards, ensuring its purity and efficacy to meet your antifungal application needs. Whether you are a pharmaceutical company, cosmetic brand, or health supplement company, we can meet your needs with high-quality Bulk Liranaftate.
Want to learn more about Bulk Liranaftate or other pharmaceutical intermediates? We'd love to connect. Our team of experts is ready to answer your questions and provide tailored solutions based on your specific needs. Please contact us today at allen@faithfulbio.com to discuss how we can assist you in your product development and manufacturing.
References
- AK Scientific. (n.d.). Liranaftate (CAS 88678-31-3). Retrieved April 7, 2026.
- National Center for Biotechnology Information. (2025). Liranaftate. PubChem Compound Summary for CID 3936. Retrieved April 7, 2026. Retrieved April 7, 2026.
- Oku, Y., Sakuma, K., Yokoyama, K., & Takase, M. (2002). Fungicidal activity of liranaftate against Trichophyton rubrum. Japanese Journal of Medical Mycology, 43(3), 181-187.
- Wang, Y., Shen, Y. N., Zhu, H. M., Zhang, L. J., Hu, F., Wen, H., Liu, W. D., & Gu, J. (2007). Liranaftate cream in the treatment of tinea cruris, tinea corporis and tinea pedis: A multicentre, randomized, double-blind, controlled trial. Chinese Journal of Dermatology, 40(8), 469-471.
- Tokyo Chemical Industry. (n.d.). Liranaftate (Product No. L0301). Retrieved April 7, 2026.Retrieved April 7, 2026.
- Inoue, T., & Oku, Y. (2024). Anti-fungal drug liranaftate suppresses fungal element-promoted production of IL-8 in normal human keratinocytes. Journal of Dermatological Science, 114(2), 101-108.